Humana (HUM) Set to Post Quarterly Earnings on Friday

Humana (NYSE:HUM) is expected to be posting its Q3 2026 results before the market opens on Friday, November 6th. Analysts expect Humana to announce earnings of ($1.00) per share and revenue of $40.87 billion for the quarter. Individuals may visit the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Friday, November 6, 2026 at 8:00 AM ET.

Humana Stock Performance

NYSE:HUM opened at $417.70 on Wednesday. The stock has a market cap of $50.16 billion, a P/E ratio of 39.52, a PEG ratio of 2.53 and a beta of 0.65. The company has a quick ratio of 1.74, a current ratio of 1.74 and a debt-to-equity ratio of 0.62. The business’s 50-day moving average price is $402.16 and its two-hundred day moving average price is $310.09. Humana has a twelve month low of $163.11 and a twelve month high of $456.50.

Humana Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 29th. Investors of record on Thursday, December 24th will be given a $0.8850 dividend. This represents a $3.54 annualized dividend and a dividend yield of 0.8%. The ex-dividend date is Thursday, December 24th. Humana’s dividend payout ratio is 33.49%.

Analyst Upgrades and Downgrades

HUM has been the topic of a number of recent analyst reports. Evercore raised shares of Humana from an “in-line” rating to an “outperform” rating and set a $480.00 target price on the stock in a research note on Wednesday, July 29th. Monness Crespi & Hardt raised shares of Humana to a “buy” rating in a report on Friday, October 9th. Weiss Ratings upgraded shares of Humana from a “hold (c-)” rating to a “hold (c)” rating in a research report on Friday, August 14th. Oppenheimer lifted their price objective on shares of Humana from $475.00 to $525.00 and gave the stock an “outperform” rating in a report on Monday, October 12th. Finally, UBS Group upped their target price on shares of Humana from $405.00 to $495.00 and gave the stock a “neutral” rating in a research report on Monday, October 12th. Twenty-one investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $453.30.

About Humana

Humana Inc is a health and well-being company that provides insurance products and health care services in the United States and Puerto Rico. The company’s primary business is government-sponsored health coverage, particularly Medicare Advantage plans for older adults, along with Medicare prescription drug plans, Medicaid coverage and certain commercial health insurance products.

Humana also operates CenterWell, its health care services platform focused on older adults. CenterWell includes primary care clinics, home health services and pharmacy services, with an emphasis on coordinated care, chronic-condition management and helping members receive care in lower-cost settings.

Founded in 1961 as a nursing-home company, Humana expanded into hospital operations before shifting its focus toward health insurance and related services.